The content of inflammatory chemokines, cytokines and indicators of neurodegradation of blood in patients with the first episode of schizophrenia at antipsychotic therapy
Suggested citation:
Sakharov AV, Mynduskin IV, Tereshkov PP, et al. [The content of inflammatory chemokines, cytokines and indicators of neurodegradation of blood in patients with the first episode of schizophrenia at antipsychotic therapy]. Rossiiskii psikhiatricheskii zhurnal [Russian Journal of Psychiatry]. 2021;(4):61-67. Russian
In a longitudinal prospective experimental study to study some pro-inflammatory chemokines, cytokines and neurodestruction indicators in patients with the first episode of schizophrenia during therapy with first-and second-generation antipsychotics, 40 patients with a diagnosis of F20.09 were examined, of which 20 took haloperidol and 20 risperidone. CCL2, sTREM-1, sTREM-2, TGF-β1, VILIP-1 and sRAGE in the blood serum by flow fluorimetry before the starts of therapy and after 8 weeks were determined. Before treatment, the CCL2 value exceeded the control values by 65%, sTREM-1 – by 120%, VILIP-1 – by 60%, sRAGE – by 79%. After 8 weeks of therapy with haloperidol, the blood levels of CCL2, VILIP-1, TGF-β1 continued to increase and sRAGE decreased. During the treatment with risperidone, an increase in the content of only VILIP-1 was noted, with a decrease in CCL2, TGF-β1 and sRAGE. The results indicate an increase in the central nervous system damage during the manifestation of schizophrenia, while therapy with risperidone in comparison with haloperidol has a beneficial effect on a greater number of the studied parameters.
Keywords schizophrenia; first episode; monocyte chemoattractant protein 1; triggering receptor expressed on myeloid cells; transforming growth factor beta 1; vizinin-like protein 1; end-product glycosylation receptor
1. Vasilieva AI, Govorin NV. [Neuromarkers and indicators of endothelial dysfunction in patients in the clinic of the first psychotic episode]. Zabajkal'skij medicinskij vestnik [The Transbaikalian medical bulletin]. 2011;(1):26–32. (In Russ.) 2. Govorin NV, Vasilieva AI. [The influence of haloperidol and risperidone on neuromarkers and indicators of endothelial dysfunction in patients with acute schizophrenia]. Zh Nevrol Psikhiatr Im SS Korsakova. 2011;(111(3)):54–7. (In Russ.) 3. Sakharov AV, Mynduskin IV, Tereshkov PP. [Indicators of neuro-repair in patients with the first episode of schizophrenia during antipsychotic therapy]. Sibirskij vestnik psihiatrii i narkologii [Siberian Herald of Psychiatry and Addiction Psychiatry]. 2020;(4(109)):15–20. (In Russ.) DOI: https://doi.org/10.26617/1810-3111-2020-3(108)-15-20 4. Foresti ML, Arisi GM, Katki K, et al. Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced status epilepticus. J Neuroinflammation. 2009;6:40. DOI: https://doi.org/10.1186/1742-2094-6-40; PMID: 20034406; PMCID: PMC2804573 5. Lin Y, Peng Y, Zhu C, et al. Pretreatment Serum MCP-1 Level Predicts Response to Risperidone in Schizophrenia. Shanghai Arch Psychiatry. 2017;29(5):287–94. DOI: https://doi.org/10.11919/j.issn.1002-0829.217093 6. Beumer W, Drexhage RC, De Wit H, et al. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology. 2012;37(12):1901–11. DOI: https://doi.org/10.1016/j.psyneuen.2012.04.001 7. Suárez-Calvet M, Morenas-Rodríguez E, Kleinberger G, et al. Alzheimer’s Disease Neuroimaging Initiative. Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology. Molecular Neurodegeneration. 2019;14(1):1. DOI: https://doi.org/10.1186/s13024-018-0301-5; PMID: 30630532; PMCID: PMC6327425 8. Ulrich JD, Holtzman DM. TREM2 function in Alzheimer's disease and Neurodegeneration. ACS Chemical Neuroscience. 2016;7(4):420–7. DOI: https://doi.org/10.1021/acschemneuro.5b00313; PMID: 26854967 9. Potvin S, Stip E, Sepehry AA, et al. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biological Psychiatry. 2008;63(8):801–8. DOI: https://doi.org/10.1016/j.biopsych.2007.09.024 10. Theis V, Theiss C. VEGF – a stimulus for neuronal development and regeneration in the CNS and PNS. Current Protein and Peptide Science. 2018;19(6):589–97. DOI: https://doi.org/10.2174/1389203719666180104113937; PMID: 29299985 11. Dulewicz M, Kulczyńska-Przybik A, Mroczko B. Neurogranin and VILIP-1 as molecular indicators of Neurodegeneration in Alzheimer's disease: a systematic review and meta-analysis. Int J Mol Sci. 2020;(21):8335. DOI: https://doi.org/10.3390/ijms21218335; PMID: 33172069; PMCID: PMC7664397 12. Galasko D, Bell J, Mancuso JY, et al. Alzheimer's Disease Cooperative Study. Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease. Neurology. 2014;82(17):1536–42. DOI: https://doi.org/10.1212/WNL.0000000000000364; PMID: 24696507; PMCID: PMC4011464
DOI: http://dx.doi.org/10.47877/1560-957Х-2021-10407
Article Metrics
Metrics powered by PLOS ALM